Koray AYDOĞDU, Göktürk FINDIK, Funda DEMİRAĞ, Sadi KAYA, Selim Şakir Erkmen GÜLHAN, Funda İNCEKARA, Ebru SAYILIR

Surgical management of large-cell neuroendocrine lung carcinoma: an analysis of 25 cases

Background/aim: Large-cell neuroendocrine carcinoma (LCNEC) of the lung is a relatively uncommon and aggressive subset of pulmonary neuroendocrine tumors, which include typical and atypical carcinoid, and small-cell lung cancer. LCNEC of the lung accounts for no more than 1% of all lung cancers. LCNECs show features of high-grade neuroendocrine tumors and patients with LCNEC have a very poor prognosis. Materials and methods: Twenty-five patients (22 males and 3 females; mean years 60.7; range 48 to 77 years) who underwent pulmonary resection for large-cell neuroendocrine carcinoma between January 2004 and December 2014 were investigated retrospectively. Results: Type of surgery, pathologic TNM stage, adjuvant chemotherapy, time of recurrence, site of recurrence, response to treatment, and long-term results were evaluated. The longest patient follow-up period was 83 months. One-, two-, and three-year survival rates of these patients were, respectively, 80.95%, 76.47%, and 50%. Conclusion: Complete surgical resection is the treatment of choice for early-stage LCNEC and chemotherapy after radical surgical treatment improves survival. Follow-up periods after surgery adjuvant chemotherapy will prevent recurrence and patients may survive for many years if complete surgical resection and adjuvant chemotherapy are possible.

PDF

___

1. Lim E, Goldstraw P, Nicholson AG, Travis WD, Ferolla P, Bomanji J, Rusch VW, Asamura H, Skogseid B, Baudin E et al. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 2008; 3: 1194-1201.
2. Shields TW. Pathology of carcinoma of the lung. In: Shields TW, editor. General Thoracic Surgery. 7th ed. Philadelphia, PA, USA: Lippincott Williams and Wilkins; 2009. pp. 1311-1340.
3. Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment. J Natl Compr Canc Netw 2011; 9: 1122-1129.
4. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhiq E, Flieder DB et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243- 1260.
5. Sakurai H, Asamura H. Large-cell neuroendocrine carcinoma of the lung: surgical management. Thoracic Surgery Clinics 2014; 24: 305-311.
6. Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998; 22: 526-537.
7. Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, Yamada T, Tsuchiya R, Matsuno Y. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eightyseven cases. J Thorac Cardiovasc Surg 2002; 124: 285-292.
8. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001; 91: 1992-2000.
9. Paci M, Cavazza A, Annessi V, Putrino I, Ferrari G, De Franco S, Sgarbi G. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004; 77: 1163-1167.
10. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishicawa Y, Yokose T, Jiang SX, Inouse T, Nakagawa K et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006; 24: 70-76.
11. Grand B, Cazes A, Mordant P, Foucault C, Dujon A, Guillevin EF, Barthes FP, Riquet M. High grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implications. Lung Cancer 2013; 81: 404-409.
12. Battafarano RJ, Fernandez FG, Ritter J, Meyers BF, Guthrie TJ, Cooper JD, Patterson A. Large call neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130: 166-172.
13. Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk D, Sima CS, Pietanza MC, Park BJ, Travis WD, Rusch VW. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann Thorac Surg 2011; 92: 1180-1187.
14. Veronesi G, Morandi U, Alloisio M, Terzi A, Cardillo G, Filosso P, Rea F, Facciolo F, Pelosi G, Gandini S et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 2006; 53: 111-115.
15. Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, Nakatani Y, Yoshino I. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary largecell neuroendocrine carcinoma. J Thorac Cardiovasc Surg 2009; 138: 446-453.
16. Shin AR, Shin BK, Choi JA, Oh YW, Kim HK, Kang EY. Large cell neuroendocrine carcinoma of the lung: radiologic and pathologic findings. J Comput Assist Tomogr 2000; 24: 567- 573.
17. Jung KJ, Lee KS, Han J, Kwon OJ, Kim J, Shim YM, Kim TS. Large cell neuroendocrine carcinoma of the lung: clinical, CT, and pathologic findings in 11 patients. J Thorac Imaging 2001; 16: 156-162.
18. Oshiro Y, Kusumoto M, Matsuno Y, Asamura H, Tsuchiya R, Terasaki H, Takei H, Maeshima A, Murayama S, Moriyama N. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. AJR Am J Roentgenol 2004; 182: 87-91.
19. Akata S, Okada S, Maeda J, Park J, Yoshimura M, Saito K, Kakizaki D, Abe K, Kato H. Computed tomographic findings of large cell neuroendocrine carcinoma of the lung. Clin Imaging 2007; 31: 379-384.
20. Kaira K, Murakami H, Endo M, Ohde Y, Naito T, Kondo H, Nakajima T, Yamamoto N, Takanashi T. Biological correlation of 18F-FDG uptake on PET in pulmonary neuroendocrine tumors. Anticancer Res 2013; 33: 4219-4228.
21. Hiroshima K, Abe S, Ebihara Y, Ogura S, Kikui M, Kodama T, Komatsu H, Saito Y, Sagawa M, Sato M, et al. Cytological characteristics of pulmonary large cell neuroendocrine carcinoma. Lung Cancer 2005; 48: 331-337.
22. Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg 2007; 84: 702-707.
23. Maleki Z. Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid or neuroendocrine morphology. Diagn Cytopathol 2011; 39: 159- 167.
24. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRa, PDGFRb, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005; 23: 8774-8785.
25. Zacharias J, Nicholson AG, Ladas GP, Goldstraw P. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg 2003; 75: 348-352.
26. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Baba M, Fujisawa T, Ohwada H. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer 2001; 92: 1108-1112.
27. Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, Iizasa T, Kimura H, Nakatani Y, Fujisawa T. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006; 82: 1802-1807.
28. Varlotto JM, Medford-Davis LN, Recht A, Flickinger JC, Schaefer E, Zander DS, DeCamp MM. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? J Thorac Oncol 2011; 6: 1050-1058.
29. Liang R, Chen TX, Wang ZQ, Jin KW, Zhang LY, Yan QN, Zhang HH, Wang WP. A retrospective analysis of the clinicopathological characteristics of large cell carcinoma of the lung. Exp Ther Med 2015; 9: 197-202.